ProCE Banner Activity

CME

A Discussion of the Rapidly Evolving Landscape in Endometrial Cancer: Addressing Clinical Changes, Challenges, and Disparities

Video

On-demand webcast of expert faculty presentation and case discussion on the evolving treatment landscape of endometrial cancer, including strategies for addressing clinical changes and health disparities.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 23, 2024

Expiration: April 22, 2025

Share

Faculty

Ramez N. Eskander

Ramez N. Eskander, MD

Clinical Professor of Gynecologic Oncology
Clinical Trials Office Director for Oncology at UC San Diego Health and Moores Cancer Center
Co-Director, UC San Diego Health International Patient Program
Fellowship Director, Gynecologic Oncology
Member of the GOG Foundation
Associate Clinical Trial Advisor, GOG Partners
San Diego, California

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

Shannon N. Westin

Shannon N. Westin, MD, MPH, FASCO

Professor
Medical Director, Gynecologic
Oncology Center
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Target Audience

This educational program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who treat patients with endometrial cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in the treatment of endometrial cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the underlying molecular biology of endometrial cancer and the rationale for precision approaches to treatment

  • Order and interpret molecular testing to aid in optimal therapy selection for patients with endometrial cancer

  • Plan individualized treatment strategies for patients with newly diagnosed and recurrent or relapsed endometrial cancer that incorporate approved and novel therapies and combination strategies

  • Identify patients with endometrial cancer who are at high risk for poor outcomes because of racial/ethnic, socioeconomic, or other demographic features

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Ramez N. Eskander, MD

Clinical Professor of Gynecologic Oncology
Clinical Trials Office Director for Oncology at UC San Diego Health and Moores Cancer Center
Co-Director, UC San Diego Health International Patient Program
Fellowship Director, Gynecologic Oncology
Member of the GOG Foundation
Associate Clinical Trial Advisor, GOG Partners
San Diego, California

Ramez N. Eskander, MD: consultant/advisor/speaker: AstraZeneca, Caris, Clovis Oncology, Daiichi Sankyo, Eisai, GlaxoSmithKline, ImmunoGen, Merck/MSD, Mersana, Myriad, Nuvectis, PMV, Regeneron, Seagen.

Shannon N. Westin, MD, MPH, FASCO

Professor
Medical Director, Gynecologic
Oncology Center
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH, FASCO: researcher: AstraZeneca, Avenge Bio, Bayer, BioPath, Clovis/Pharma&, GlaxoSmithKline, Jazz Pharmaceuticals, Mereo, Novartis, Nuvectis, Roche/Genentech, Zentalis; consultant/advisor/speaker: AstraZeneca, Caris, Clovis/Pharma&, Eisai, EQRx, Gilead, GlaxoSmithKline, Immunocore, ImmunoGen, Lilly, Loxo, Mereo, Mersana, NGM Bio, Nuvectis, Roche/Genentech, Seagen, Verastem, Vincerx, Zentalis, ZielBio.

Contributing Author

David Scott Miller, MD, FACOG, FACS

Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas

David Scott Miller, MD, FACOG, FACS: consultant/advisor: AbbVie, Agenus, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical Research Institute, Eisai, Eisai Europe Limited, EMD Serono, GlaxoSmithKline, ImmunoGen, Incyte, iTeos Belgium SA, Karyopharm, Merck Sharp & Dohme, Myriad Genetic Laboratories, Novartis, Novocure, Seagen, Tarveda Therapeutics; researcher: EMD Serono, Leap Therapeutics, US Biotest; researcher (paid to institution): Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akeso, Aprea, AstraZeneca, ImmunoGen, Incyte, Janssen, Karyopharm, Mateon, Merck Sharp & Dohme, Millennium, Novartis, NVision, Pfizer, Regeneron, Syros, Tesaro, TRACON Pharma, Xenetic Biosciences.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 23, 2024, through April 22, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.